Relay Therapeutics reports 9.2-month median progression-free survival with RLY-2608 in first-in-human study for HR+, HER2- breast cancer patients.
Relay Therapeutics has reported promising interim results for RLY-2608 in a first-in-human study for patients with PI3Kα-mutated, HR+, HER2- breast cancer. The drug, combined with fulvestrant, showed a median progression-free survival of 9.2 months in heavily pre-treated patients. The company plans to initiate a pivotal trial next year and is seeking a commercialization partner for lirafugratinib. Relay's financial position is strong, with $688 million projected to sustain operations into 2026.
September 09, 2024
4 Articles